Skip to main navigation
Skip to search
Skip to main content
Albert Einstein College of Medicine Home
Home
Faculty
Departments
Grants
Publications
Prizes
Search by expertise, name or affiliation
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial
ACTT-4 Study Group
Medicine
Research output
:
Contribution to journal
›
Article
›
peer-review
61
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
GS-5734
100%
baricitinib
85%
Dexamethasone
43%
Placebos
32%
Artificial Respiration
11%
Noninvasive Ventilation
6%
Hispanic Americans
4%
Survival
4%
National Institute of Allergy and Infectious Diseases (U.S.)
3%
SARS Virus
3%
Alaska Natives
3%
Oxygen
3%
North American Indians
2%
Republic of Korea
2%
Singapore
2%
Immunomodulation
2%
Mexico
2%
Kaplan-Meier Estimate
2%
Random Allocation
2%
Intention
2%
Japan
2%
Population
1%
Comorbidity
1%
Therapeutics
1%
Odds Ratio
1%
Costs and Cost Analysis
1%
Safety
1%
Infections
1%
Pharmaceutical Preparations
1%